The Role of P-Glycoprotein (P-gp) in Cancer Multidrug Resistance (MDR): Challenges for Inhibiting P-gp in the Context of Overcoming MDR

Multidrug resistance (MDR), as is well known, regarded the primary factor in cancer therapy failure. A common mechanism of MDR anticancer drugs expression P-glycoprotein (P-gp), a class ATP-dependent membrane transport efflux pumps called adenosine triphosphate (ATP)-binding cassette (ABC) transporters. It xenobiotics outside cell and plays part typical physiological detoxification host defense activities. This transporter distributed gastrointestinal mucosa epithelial surfaces, blood-tissue barriers, hepatic biliary epithelium, proximal tubules kidney, adrenal cortex. P-gp known to be responsible for because its over-expression malignant cells. functions an pump lowering concentration intracellularly, thus decreasing effectiveness chemotherapy. Although using multiple medications good strategy, Cancerous cells are able develop MDR. number chemically synthesized inhibitors were investigated overcome clinical studies. Additionally, certain natural compounds have been observed modulate P-gp. Numerous investigations on strategies conducted result significant impact chemotherapeutic drug resistance. review discusses role challenges inhibiting context overcoming mediated by concluded that discovery selective, safe, potent remains necessary.